Protocol Ledger

NCT05583526 · Phase III · COMPLETED

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

Interventional Phase III clinical trial protocol NCT05583526 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-01 Enrollment: 607 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05583526
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)607 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05583526
Protocol FieldVerified Registry Value
NCT IdentifierNCT05583526
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment607 participants (ACTUAL)
Registered Start Date2022-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI